ABVC BIOPHARMA INC (ABVC)

US00091F3047 - Common Stock

0.5157  -0.01 (-2.7%)

Premarket: 0.5207 +0.01 (+0.97%)

Fundamental Rating

2

Overall ABVC gets a fundamental rating of 2 out of 10. We evaluated ABVC against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of ABVC have multiple concerns. ABVC is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABVC has reported negative net income.
ABVC had a negative operating cash flow in the past year.
In the past 5 years ABVC always reported negative net income.
ABVC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ABVC's Return On Assets of -57.00% is in line compared to the rest of the industry. ABVC outperforms 43.01% of its industry peers.
With a Return On Equity value of -98.62%, ABVC perfoms like the industry average, outperforming 46.37% of the companies in the same industry.
Industry RankSector Rank
ROA -57%
ROE -98.62%
ROIC N/A
ROA(3y)-110.94%
ROA(5y)-93.93%
ROE(3y)-266.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ABVC's Gross Margin of 72.54% is amongst the best of the industry. ABVC outperforms 83.89% of its industry peers.
ABVC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

ABVC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABVC has been increased compared to 1 year ago.
Compared to 5 years ago, ABVC has more shares outstanding
Compared to 1 year ago, ABVC has an improved debt to assets ratio.

2.2 Solvency

ABVC has an Altman-Z score of -7.93. This is a bad value and indicates that ABVC is not financially healthy and even has some risk of bankruptcy.
ABVC has a worse Altman-Z score (-7.93) than 70.27% of its industry peers.
ABVC has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
ABVC's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. ABVC is outperformed by 66.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -7.93
ROIC/WACCN/A
WACC9.98%

2.3 Liquidity

ABVC has a Current Ratio of 0.34. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.34, ABVC is doing worse than 95.40% of the companies in the same industry.
ABVC has a Quick Ratio of 0.34. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
ABVC has a Quick ratio of 0.34. This is amonst the worse of the industry: ABVC underperforms 94.69% of its industry peers.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.34

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.30% over the past year.
The Revenue for ABVC has decreased by -31.65% in the past year. This is quite bad
Measured over the past years, ABVC shows a very strong growth in Revenue. The Revenue has been growing by 72.43% on average per year.
EPS 1Y (TTM)72.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.16%
Revenue 1Y (TTM)-31.65%
Revenue growth 3Y-31.78%
Revenue growth 5Y72.43%
Sales Q2Q%2351.39%

3.2 Future

The Earnings Per Share is expected to decrease by -28.17% on average over the next years. This is quite bad
Based on estimates for the next years, ABVC will show a very strong growth in Revenue. The Revenue will grow by 245.77% on average per year.
EPS Next Y-57.14%
EPS Next 2Y-28.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y245.77%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABVC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABVC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ABVC's earnings are expected to decrease with -28.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.17%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABVC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABVC BIOPHARMA INC

NASDAQ:ABVC (1/14/2025, 8:21:42 PM)

Premarket: 0.5207 +0.01 (+0.97%)

0.5157

-0.01 (-2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners2.95%
Inst Owner Change0%
Ins Owners15.83%
Ins Owner Change0%
Market Cap6.69M
Analysts43.33
Price TargetN/A
Short Float %3.56%
Short Ratio1.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.13
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.04
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57%
ROE -98.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.54%
FCFM N/A
ROA(3y)-110.94%
ROA(5y)-93.93%
ROE(3y)-266.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.34
Altman-Z -7.93
F-Score4
WACC9.98%
ROIC/WACCN/A
Cap/Depr(3y)291.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.61%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.16%
EPS Next Y-57.14%
EPS Next 2Y-28.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-31.65%
Revenue growth 3Y-31.78%
Revenue growth 5Y72.43%
Sales Q2Q%2351.39%
Revenue Next Year-100%
Revenue Next 2Y245.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.06%
OCF growth 3YN/A
OCF growth 5YN/A